Geron Corporation (GERN) Reports Q4 EPS of (5c)

Geron Corporation (NASDAQ:GERN) is among the 11 Fastest Growing Penny Stocks to Buy Right Now.

Geron Corporation (GERN) Reports Q4 EPS of (5c)

On February 25, 2026, Geron Corporation (NASDAQ:GERN) reported fourth-quarter EPS of (5c), compared with consensus estimates of (4c), and revenue of $48M versus consensus of $50.43M. CEO Harout Semerjian said strategic actions taken in the second half of 2025 were intended to position the company to drive RYTELO demand while lowering total operating expenses year over year. Semerjian highlighted the commercial opportunity for RYTELO in second-line lower-risk MDS, citing support from its FDA label, NCCN Guidelines, and expanding scientific evidence. The company also expects catalysts in the second half of 2026, including the IMpactMF interim analysis in relapsed or refractory myelofibrosis and initial data from real-world experience trials evaluating RYTELO in LR-MDS.

For fiscal year 2026, Geron Corporation (NASDAQ:GERN) expects Rytelo net product revenue of $220M to $240M and total operating expenses of $230M to $240M. The company said existing cash, cash equivalents, restricted cash, and marketable securities, together with anticipated U.S. sales of Rytelo, should be sufficient to fund operating requirements for the foreseeable future.

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company focused on developing therapeutic products for oncology.

While we acknowledge the potential of GERN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GERN and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey on Google News.